Prognostic Values of Common Clinical Parameters in Advanced Pancreatic Ductal Adenocarcinoma: a Large Multicenter Cohort Study of Ten Years
Chenyue Zhang,Shu Dong,Lei Wang,Songlin Yu,Yuwei Zheng,Yanyan Geng,Xiaoheng Shen,Haifeng Ying,Yuanbiao Guo,Jinming Yu,Qinglong Deng,Zhiqiang Meng,Zhaoshen Li,Hao Chen,Yehua Shen,Qiwen Chen
2018-01-01
Discovery medicine
Abstract:Objective: We conducted a multicenter cohort study to investigate the prognostic value of some commonly-used laboratory indices in advanced pancreatic ductal adenocarcinoma (PDAC). Methods: A multicenter cohort study was conducted from 2004 to 2013. The associations between laboratory indices and prognosis of advanced PDAC were examined. Results: This cohort consisted of 553 females (36.2%) and 973 males (63.8%). Patients at cancer stage III and IV were 595 (39.0%) and 931 (61.0%), respectively. The median survival of stage III patients was 9.0 months, with 3-, 6-, and 12-month survival rates of 94.5%, 73.4%, and 28.5%, respectively. The median survival of stage IV patients was 5.4 months, with 3-, 6, and 12-month survival rates of 79.3%, 42.9%, and 15.0%, respectively. In multivariate analyses, primary tumor diameter, low albumin, and elevated CA19-9 were associated with decreased survival for stage III patients. Age, smoking, primary tumor diameter, elevated ALT or AST, low albumin, and elevated CA19-9 were associated with decreased survival for stage IV patients. Conclusion: Elevated CA19-9 level, decreased albumin level, and tumor size were associated with worse survival in stage III patients. Meanwhile, advanced age, smoking, and ALT or AST level were negatively correlated to prognosis in stage IV patients.